Hemostatic changes in active pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 10, 2002, Pages 927-932

  Turken, O ^a   Kunter, Erdogan ^a   Sezer, M ^a   Solmazgul, E ^a   Cerrahoglu, K ^a   Bozkanat, E ^a   Ozturk, A ^a   Ilvan, A ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antithrombin III; Hypercoagulability; Plasminogen activator inhibitor; Protein C; Tuberculosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANEMIA; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LEUKOCYTOSIS; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOSIS; VEIN THROMBOSIS;

ADULT; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; HEMATOLOGIC DISEASES; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS, PULMONARY; VENOUS THROMBOSIS;

EID: 0036798545     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. White N W. Venous thrombosis and rifampicin. Lancet 1989; 2: 434-435.
2. Anderson F A, Wheeler H B, Goldberg R J, Hosmer D W, Forcier A. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-595.
3. Dinarello C A. Interleukin-1 and pathogenesis of the acutephase response. N Engl J Med 1984; 311: 1413-1418.
4. Schafer A L. The hypercoagulable states. Ann Int Med 1985; 102: 814-828.
5. Griffin J H, Ewatt B, Wideman C, Fernandez J A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993.
6. Swenson P, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
7. Ogawa T, Uchida H, Kusumoto Y, Mori Y, Yamamura Y, Hamada S. Increase in tumor necrosis factor alpha and interleukin-6 secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immunol 1991; 59: 3021-3025.
8. Hua C C, Chang L C, Chen Y C, Chang S C. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions. Chest 1999; 116: 1292-1296.
9. Rook G A W, Al Attiyah R. Cytokines and the Koch phenomenon. Tubercle 1991; 72: 13-20.
10. Gauldie J, Northemann W, Fey G H. IL-6 functions as an exocrine hormone in inflammation: Hepatocytes undergoing acute-phase responses require exogenous IL-6. J Immunol 1990;144:3804-3808.
11. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 364-375.
12. Bevilacqua M P, Pober J S, Majeau G R, Cotran R S, Gimbrone M A. Interleukin-1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Experiment 1984; 160: 618-623.
13. Koster T, Rosendaal F R, de Ronde A, Brier E, van den Broucke J P, Bertina R M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
14. Sawaya R, Ramao O J, Glas-Greenwalt P. Plasma fibrinolytic profile in patients with brain tumors. Thromb Haemost 1991; 23: 15-19.
15. Sucha N, Messmore H. Hemostasis in malignancy. Am J Hematol 1990; 35: 45-55.
16. Lindahl A K, Odegaard O R, Sandset P M, Harbitz T B. Coagulation inhibition and activation in pancreatic cancer. Changes during progressive disease. Cancer 1992; 70: 2067-2072.
17. Robson S C, White N W, Aronson I, Woolgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. B J Haematol 1996; 93: 943-949.
18. Monroy V, Amador A, Ruiz B, et al. Binding and activation of human plasminogen by Mycobacterium tuberculosis. Infect Immun 2000; 68: 4327-4330.
19. Juffermans N P, Dekkers P E, Verbron A, Speelman P, Van Deventer S J, van der Poll T. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun 2001;69:5182-5185.
20. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1992; 34: 179-192.
21. Meade T W, Vickers M V, Thompson S G, Stirling Y, Haines A P, Miller G J. Epidemiological characteristics of platelet aggregability. B M J 1985; 290: 428-432.
22. Cortes J, Stinson V, Salomaa V. Platelet activation and early carotid atherosclerosis: the ARIC study. Thromb Haemost 1993; 69: 1115-1116.
23. Ten Cate J W, Vos J, Oosterhuis H, Prenger D, Jenkins C S. Spontaneous platelet aggregation in cerebrovascular disease. Thromb Haemost 1978; 39: 223-229.
24. Bertina R M, Koeleman B P C, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
25. Buyukasik Y, Soylu B, Soylu A R, et al. In vivo platelet and T-lymphocyte activities during pulmonary tuberculosis. Eur Respir J 1998; 12: 1375-1379.
26. Dahlback B. Inherited thrombophilia: Resistance to activated protein C as a pathogenetic factor of venous thromboembolism. Blood 1995; 85: 607-614.